newsfilter
← Latest News
GlobeNewswire·

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the